129 related articles for article (PubMed ID: 38617451)
21. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
22. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
[TBL] [Abstract][Full Text] [Related]
23. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
24. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials.
Zhao X; Ren Y; Hu Y; Cui N; Wang X; Cui Y
PLoS One; 2018; 13(8):e0202185. PubMed ID: 30138325
[TBL] [Abstract][Full Text] [Related]
26. Application of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in curative surgery for esophageal cancer: A meta-analysis.
Yuan MX; Cai QG; Zhang ZY; Zhou JZ; Lan CY; Lin JB
World J Gastrointest Oncol; 2024 Jan; 16(1):214-233. PubMed ID: 38292844
[TBL] [Abstract][Full Text] [Related]
27. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis.
Jin HL; Zhu H; Ling TS; Zhang HJ; Shi RH
World J Gastroenterol; 2009 Dec; 15(47):5983-91. PubMed ID: 20014464
[TBL] [Abstract][Full Text] [Related]
29. Omitting surgery in esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.
Park J; Yea JW; Oh SA; Park JW
Radiat Oncol; 2021 Nov; 16(1):219. PubMed ID: 34775988
[TBL] [Abstract][Full Text] [Related]
30. Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study).
Zhou HY; Zheng SP; Li AL; Gao QL; Ou QY; Chen YJ; Wu ST; Lin DG; Liu SB; Huang LY; Li FS; Zhu HY; Qiao GB; Lanuti M; Yao HR; Yu YF
EClinicalMedicine; 2020 Jul; 24():100422. PubMed ID: 32637899
[TBL] [Abstract][Full Text] [Related]
31. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial.
Noordman BJ; Verdam MGE; Lagarde SM; Shapiro J; Hulshof MCCM; van Berge Henegouwen MI; Wijnhoven BPL; Nieuwenhuijzen GAP; Bonenkamp JJ; Cuesta MA; Plukker JTM; Spillenaar Bilgen EJ; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB;
Ann Oncol; 2018 Feb; 29(2):445-451. PubMed ID: 29126244
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
[TBL] [Abstract][Full Text] [Related]
33. Concurrent radiotherapy cannot provide superiority of surgical oncological outcome and long-term survival rate in locally advanced esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy followed by minimally invasive esophagectomy.
Wang YJ; Bao T; Li KK; Xie XF; He XD; Zhao XL; Guo W
Surg Endosc; 2023 Sep; 37(9):7073-7082. PubMed ID: 37380741
[TBL] [Abstract][Full Text] [Related]
34. Comparison of different neoadjuvant treatments for resectable locoregional esophageal cancer: A systematic review and network meta-analysis.
Bao Y; Ma Z; Yuan M; Wang Y; Men Y; Hui Z
Thorac Cancer; 2022 Sep; 13(17):2515-2523. PubMed ID: 35891585
[TBL] [Abstract][Full Text] [Related]
35. Meta-Analysis for the Therapeutic Effect of Neoadjuvant Therapy in Resectable Esophageal Cancer.
Zhu Y; Liu M; Yun X; Wang D; Bai Y; Zhang G; Ji B; Jing C
Pathol Oncol Res; 2017 Jul; 23(3):657-663. PubMed ID: 28013492
[TBL] [Abstract][Full Text] [Related]
36. Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer.
Borggreve AS; Heethuis SE; Boekhoff MR; Goense L; van Rossum PSN; Brosens LAA; van Lier ALHMW; van Hillegersberg R; Lagendijk JJW; Mook S; Ruurda JP; Meijer GJ
Eur Radiol; 2020 Apr; 30(4):1896-1907. PubMed ID: 31822974
[TBL] [Abstract][Full Text] [Related]
37. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis.
Li F; Ding N; Zhao Y; Yuan L; Mao Y
Int J Surg; 2018 Dec; 60():88-100. PubMed ID: 30389537
[TBL] [Abstract][Full Text] [Related]
38. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Klevebro F; Alexandersson von Döbeln G; Wang N; Johnsen G; Jacobsen AB; Friesland S; Hatlevoll I; Glenjen NI; Lind P; Tsai JA; Lundell L; Nilsson M
Ann Oncol; 2016 Apr; 27(4):660-7. PubMed ID: 26782957
[TBL] [Abstract][Full Text] [Related]
39. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
Lin G; Han SY; Xu YP; Mao WM
Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
[TBL] [Abstract][Full Text] [Related]
40. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
